Financial Insights, Inc. Viking Therapeutics, Inc. Transaction History

Financial Insights, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$9.24 - $19.64 $138,600 - $294,600	-15,000 Closed	0 $0
Q2 2023 Jan 24, 2024	BUY	$14.84 - $24.79 $222,600 - $371,850	15,000 New	15,000 $243,000
Q1 2023 Apr 17, 2023	BUY	$8.08 - $17.33 $8,080 - $17,330	1,000 Added 7.14%	15,000 $249,000
Q4 2022 Feb 09, 2023	SELL	$2.72 - $9.4 $38,080 - $131,600	-14,000 Reduced 50.0%	14,000 $131,000
Q3 2022 Oct 26, 2022	BUY	$2.55 - $3.89 $71,400 - $108,920	28,000 New	28,000 $76,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Financial Insights, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Insights, Inc. with notifications on news.